SUMMARY OF INDIRECT COMPARISON TO EVALUATE EFFICACY OF BARICITINIB WITH TARGETED SYNTHETIC AND BIOLOGIC DISEASE ANTI-RHEUMATIC DRUGS IN PATIENTS WITH RHEUMATOID ARTHRITIS

被引：0

作者：

Emery, Paul ^{[1
]}

Dudler, Jean ^{[2
]}

Smolen, Josef ^{[3
]}

Zerbini, Cristiano ^{[4
]}

Burmester, Gerd ^{[5
]}

Fautrel, Bruno ^{[6
]}

van der Laar, Mart ^{[7
]}

Fleischmann, Roy ^{[8
]}

Fakhouri, Walid ^{[9
]}

De Leonardis, Francesco ^{[10
]}

Zhu, Baojin ^{[11
]}

Kadziola, Zbigniew ^{[12
]}

De La Torre, Inmaculada ^{[13
]}

Perrier, Clementine ^{[14
]}

Taylor, Peter C. ^{[15
]}

机构：

[1] Leeds MSK Biomed Chapel Allerton Hosp, Fac Med & Hlth, Leeds, W Yorkshire, England

[2] HFR Fribourg Hop Cantonal, Dept Rheumatol, Fribourg, Switzerland

[3] Med Univ Vienna, Dept Rheumatol, Vienna, Austria

[4] Ctr Invest Clin, Dept Rheumatol, Sao Paulo, Brazil

[5] Charite Univ Med Berlin, Dept Rheumatol & Clin Immunol, Berlin, Germany

[6] Pierre & Marie Curie Univ, Dept Rheumatol, Paris, France

[7] Arthrit Ctr Twente, Dept Rheumatol, Enschede, Netherlands

[8] Univ Texas Southwestern Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA

[9] Eli Lilly & Co, Global Hlth Outcomes, Indianapolis, IN 46285 USA

[10] Eli Lilly & Co, Dept Rheumatol, Indianapolis, IN 46285 USA

[11] Eli Lilly & Co, Real World Analyt Immunol, Indianapolis, IN 46285 USA

[12] Eli Lilly & Co, Real World Analyt Capabil & Data Mart, Indianapolis, IN 46285 USA

[13] Eli Lilly & Co, Dept Med, Indianapolis, IN 46285 USA

[14] Eli Lilly & Co, Dept Med Autoimmune, Indianapolis, IN 46285 USA

[15] Univ Oxford, Botnar Res Ctr, NDORMS, Headington, England

来源：

RHEUMATOLOGY | 2019年 / 58卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

074

引用

页数：2

共 50 条

[21] THE MODERATING EFFECTS OF DEPRESSION ON BIOLOGIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS IN RHEUMATOID ARTHRITIS
Rathbun, A. M.
Harrold, L. R.
Reed, G. W.
ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 631 - 631
[22] Predictors at Diagnosis for Start of Biologic Disease Modifying Anti-Rheumatic Drugs in Patients with Early Rheumatoid Arthritis
Hameed, M.
Exarchou, S.
Eberhard, A.
Sharma, A.
Bergstrom, U.
Einarsson, J.
Turesson, C.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2023, 52 : 67 - 68
[23] Biologic disease-modifying anti-rheumatic drugs and kinase inhibitors: differences in efficacy and safety in rheumatoid arthritis
Roy Fleischmann
Clinical Rheumatology, 2021, 40 : 4369 - 4372
[24] Predictors at Diagnosis for Start of Biologic Disease Modifying Anti-Rheumatic Drugs in Patients with Early Rheumatoid Arthritis
Hameed, Mohaned
Exarchou, Sofia
Eberhard, Anna
Sharma, Ankita
Bergstrom, Ulf
Einarsson, Jon
Turesson, Carl
ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 2831 - 2833
[25] Biologic disease-modifying anti-rheumatic drugs and kinase inhibitors: differences in efficacy and safety in rheumatoid arthritis
Fleischmann, Roy
CLINICAL RHEUMATOLOGY, 2021, 40 (11) : 4369 - 4372
[26] LOSS OF EFFICACY OF ANTI-RHEUMATIC DRUGS IN RHEUMATOID-ARTHRITIS
ROSENTHAL, M
JOURNAL OF RHEUMATOLOGY, 1980, 7 (04) : 586 - 587
[27] Tailored first-line biologic and targeted synthetic disease modifying anti-rheumatic drugs therapy in patients with rheumatoid arthritis: 2021 updated ITABIO statements
Cantini, Fabrizio
Goletti, Delia
Benucci, Maurizio
Foti, Rosario
Damiani, Arianna
Niccoli, Laura
EXPERT OPINION ON DRUG SAFETY, 2022, 21 (05) : 613 - 623
[28] Use of biologic or targeted-synthetic disease-modifying anti-rheumatic drugs and risk of diabetes treatment intensification in patients with rheumatoid arthritis and diabetes mellitus
Chen, Sarah K.
Lee, Hemin
Jin, Yinzhu
Liu, Jun
Kim, Seoyoung C.
RHEUMATOLOGY ADVANCES IN PRACTICE, 2020, 4 (02) : 1 - 11
[29] Differences in trajectory of disease activity according to biologic and targeted synthetic disease-modifying anti-rheumatic drug treatment in patients with rheumatoid arthritis
Bon San Koo
Seongho Eun
Kichul Shin
Seokchan Hong
Yong-Gil Kim
Chang-Keun Lee
Bin Yoo
Ji Seon Oh
Arthritis Research & Therapy, 24
[30] Differences in trajectory of disease activity according to biologic and targeted synthetic disease-modifying anti-rheumatic drug treatment in patients with rheumatoid arthritis
San Koo, Bon
Eun, Seongho
Shin, Kichul
Hong, Seokchan
Kim, Yong-Gil
Lee, Chang-Keun
Yoo, Bin
Oh, Ji Seon
ARTHRITIS RESEARCH & THERAPY, 2022, 24 (01)

← 1 2 3 4 5 →